131 related articles for article (PubMed ID: 18462811)
1. Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation.
Fazzino F; Montes C; Urbina M; Carreira I; Lima L
J Neuroimmunol; 2008 May; 196(1-2):173-80. PubMed ID: 18462811
[TBL] [Abstract][Full Text] [Related]
2. Serotonin, 5-HT1A serotonin receptors and proliferation of lymphocytes in major depression patients.
González A; Fazzino F; Castillo M; Mata S; Lima L
Neuroimmunomodulation; 2007; 14(1):8-15. PubMed ID: 17700035
[TBL] [Abstract][Full Text] [Related]
3. Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients.
Peña S; Baccichet E; Urbina M; Carreira I; Lima L
Int Immunopharmacol; 2005 Jun; 5(6):1069-76. PubMed ID: 15829422
[TBL] [Abstract][Full Text] [Related]
4. Noradrenaline transporter and its turnover rate are decreased in blood lymphocytes of patients with major depression.
Mata S; Urbina M; Manzano E; Ortiz T; Lima L
J Neuroimmunol; 2005 Dec; 170(1-2):134-40. PubMed ID: 16242784
[TBL] [Abstract][Full Text] [Related]
5. Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: a flow cytometric analysis.
Başterzi AD; Yazici K; Buturak V; Cimen B; Yazici A; Eskandari G; Tot Acar S; Taşdelen B
Prog Neuropsychopharmacol Biol Psychiatry; 2010 Feb; 34(1):70-5. PubMed ID: 19804808
[TBL] [Abstract][Full Text] [Related]
6. Fluoxetine directly counteracts the adverse effects of chronic stress on T cell immunity by compensatory and specific mechanisms.
Frick LR; Rapanelli M; Cremaschi GA; Genaro AM
Brain Behav Immun; 2009 Jan; 23(1):36-40. PubMed ID: 18625298
[TBL] [Abstract][Full Text] [Related]
7. Fluoxetine treatment to rats modifies serotonin transporter and cAMP in lymphocytes, CD4+ and CD8+ subpopulations and interleukins 2 and 4.
Fazzino F; Urbina M; Cedeño N; Lima L
Int Immunopharmacol; 2009 Apr; 9(4):463-7. PubMed ID: 19189865
[TBL] [Abstract][Full Text] [Related]
8. HPA axis activation in major depression and response to fluoxetine: a pilot study.
Young EA; Altemus M; Lopez JF; Kocsis JH; Schatzberg AF; DeBattista C; Zubieta JK
Psychoneuroendocrinology; 2004 Oct; 29(9):1198-204. PubMed ID: 15219644
[TBL] [Abstract][Full Text] [Related]
9. Leukocyte subsets in treatment-resistant major depression.
Kubera M; Van Bockstaele D; Maes M
Pol J Pharmacol; 1999; 51(6):547-9. PubMed ID: 10817536
[TBL] [Abstract][Full Text] [Related]
10. Serotonin, serotonin 5-HT(1A) receptors and dopamine in blood peripheral lymphocytes of major depression patients.
Fajardo O; Galeno J; Urbina M; Carreira I; Lima L
Int Immunopharmacol; 2003 Sep; 3(9):1345-52. PubMed ID: 12890432
[TBL] [Abstract][Full Text] [Related]
11. Serotonin transporter modulation in blood lymphocytes from patients with major depression.
Lima L; Urbina M
Cell Mol Neurobiol; 2002 Dec; 22(5-6):797-804. PubMed ID: 12585696
[TBL] [Abstract][Full Text] [Related]
12. Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?
Castrogiovanni P; Blardi P; De Lalla A; Dell'Erba A; Auteri A
Psychopharmacol Bull; 2003; 37(2):102-8. PubMed ID: 14566218
[TBL] [Abstract][Full Text] [Related]
13. Gender based response to fluoxetine hydrochloride medication in endogenous depression.
Bano S; Akhter S; Afridi MI
J Coll Physicians Surg Pak; 2004 Mar; 14(3):161-5. PubMed ID: 15228850
[TBL] [Abstract][Full Text] [Related]
14. Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression.
Lima L; Mata S; Urbina M
Neuroimmunomodulation; 2005; 12(5):299-306. PubMed ID: 16166809
[TBL] [Abstract][Full Text] [Related]
15. Cortisol level in men with major depressive disorder treated with fluoxetine or imipramine.
Piwowarska J; Dryll K; Szelenberger W; Pachecka J
Acta Pol Pharm; 2008; 65(1):159-64. PubMed ID: 18536191
[TBL] [Abstract][Full Text] [Related]
16. Lymphocyte subsets and viral load in male AIDS patients with major depression: naturalistic study.
Huang TL; Leu HS; Liu JW
Psychiatry Clin Neurosci; 2006 Dec; 60(6):687-92. PubMed ID: 17109702
[TBL] [Abstract][Full Text] [Related]
17. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
18. Mouse strain differences in immobility and sensitivity to fluvoxamine and desipramine in the forced swimming test: analysis of serotonin and noradrenaline transporter binding.
Sugimoto Y; Kajiwara Y; Hirano K; Yamada S; Tagawa N; Kobayashi Y; Hotta Y; Yamada J
Eur J Pharmacol; 2008 Sep; 592(1-3):116-22. PubMed ID: 18655786
[TBL] [Abstract][Full Text] [Related]
19. Plasma catecholamine levels after fluoxetine treatment in depressive patients.
Blardi P; de Lalla A; Auteri A; Iapichino S; Dell'Erba A; Castrogiovanni P
Neuropsychobiology; 2005; 51(2):72-6. PubMed ID: 15741747
[TBL] [Abstract][Full Text] [Related]
20. Kynurenine metabolites and inflammation markers in depressed patients treated with fluoxetine or counselling.
Mackay GM; Forrest CM; Christofides J; Bridel MA; Mitchell S; Cowlard R; Stone TW; Darlington LG
Clin Exp Pharmacol Physiol; 2009 Apr; 36(4):425-35. PubMed ID: 19018805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
